News | October 28, 2024
Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
This is used to treat central diabetes insipidus and bedwetting
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Subscribe To Our Newsletter & Stay Updated
